Clinical Trial

Antihistamines, Amantadine and Evolution of COVID-19

Recruiting
View on ClinicalTrials.gov →
Summary
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-08-15; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT05504057
Lead Sponsor Consorci Sanitari de Terrassa
Collaborators: Institut Català de la Salut
Conditions COVID-19
Enrollment 140,660 participants
Start Date 2020-03-01
Primary Completion 2025-01-19 (estimated)
Study Completion 2028-02-24 (estimated)
Updated on ClinicalTrials.gov 2026-04-03